130 related articles for article (PubMed ID: 26124331)
61. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells.
Nawata J; Kuramitsu Y; Wang Y; Kitagawa T; Tokuda K; Baron B; Akada J; Suenaga S; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2014 Sep; 34(9):4807-11. PubMed ID: 25202061
[TBL] [Abstract][Full Text] [Related]
62. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer.
Li W; Zhu Y; Zhang K; Yu X; Lin H; Wu W; Peng Y; Sun J
Exp Mol Med; 2020 Mar; 52(3):409-422. PubMed ID: 32123287
[TBL] [Abstract][Full Text] [Related]
63. A standardized extract of cultured
Islam S; Kitagawa T; Baron B; Kuhara K; Nagayasu H; Kobayashi M; Chiba I; Kuramitsu Y
Oncol Lett; 2021 Sep; 22(3):654. PubMed ID: 34386076
[TBL] [Abstract][Full Text] [Related]
64. Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus.
Jin Y; Fan Y; Yan EZ; Liu Z; Zong ZH; Qi ZM
Acta Pharmacol Sin; 2006 Oct; 27(10):1309-16. PubMed ID: 17007737
[TBL] [Abstract][Full Text] [Related]
65. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Zou J; Su H; Zou C; Liang X; Fei Z
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
[TBL] [Abstract][Full Text] [Related]
66. Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Chai X; Chu H; Yang X; Meng Y; Shi P; Gou S
Sci Rep; 2015 Sep; 5():14404. PubMed ID: 26391180
[TBL] [Abstract][Full Text] [Related]
67. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
[TBL] [Abstract][Full Text] [Related]
68. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
69. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
70. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
71. HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Ghadban T; Dibbern JL; Reeh M; Miro JT; Tsui TY; Wellner U; Izbicki JR; Güngör C; Vashist YK
Apoptosis; 2017 Mar; 22(3):369-380. PubMed ID: 27878398
[TBL] [Abstract][Full Text] [Related]
72. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
[TBL] [Abstract][Full Text] [Related]
73. Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages.
Sanghera JS; Weinstein SL; Aluwalia M; Girn J; Pelech SL
J Immunol; 1996 Jun; 156(11):4457-65. PubMed ID: 8666821
[TBL] [Abstract][Full Text] [Related]
74. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
75. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
76. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption.
Wolfson RK; Chiang ET; Garcia JG
Microvasc Res; 2011 Mar; 81(2):189-97. PubMed ID: 21146549
[TBL] [Abstract][Full Text] [Related]
77. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
78. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
79. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
80. PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma.
Alam R; Schultz CR; Golembieski WA; Poisson LM; Rempel SA
Neuro Oncol; 2013 Apr; 15(4):451-61. PubMed ID: 23382286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
